SCHEMBL1674776

SCHEMBL1674776

C=CC1=CCCCC1(C=O)C=O

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3330871 0.72 TRPV1 (0.44) TRPV1
SCHEMBL4685597 0.71 CCR2 (0.33)
SCHEMBL7152047 0.71 TRPV1 (0.30) TRPV1
SCHEMBL14993156 0.63 TRPV1 (0.50) TRPV1
SCHEMBL14993445 0.58 TRPV1 (0.46) TRPV1
SCHEMBL75132 0.52
SCHEMBL27206 0.51
SCHEMBL8586607 0.51
SCHEMBL3206624 0.49 KDM1A (0.31)
SCHEMBL10709752 0.49

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4303209-A1 METHOD FOR THE PREPARATION OF VINYLCYCLOHEXENE DIALDEHYDE Evonik Oxeno GmbH & Co. KG (DE) 2024-01-10 EP disclosed
US-9249278-B2 Cross-linkable polymer dispersions, method for the production thereof and use thereof CELANESE EMULSIONS GMBH (DE) 2016-02-02 US disclosed
CN-101657513-B Cross-linkable polymer dispersions, method for the production thereof and use thereof CELANESE EMULSIONS GMBH 2013-11-06 CN disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
EP-2137276-B1 CROSS-LINKABLE POLYMER DISPERSIONS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF CELANESE EMULSIONS GMBH (DE) 2011-04-27 EP disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179272-A1 Cross-Linkable Polymer Dispersions, Method for the Production Thereof and Use Thereof NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) 2010-07-15 US disclosed
CN-101657513-A Crosslinkable polymeric dispersions, method of its production and uses thereof CELANESE EMULSIONS GMBH 2010-02-24 CN disclosed
EP-2137276-A1 CROSS-LINKABLE POLYMER DISPERSIONS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF Celanese Emulsions GmbH (DE) 2009-12-30 EP disclosed
EP-2132178-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2009-12-16 EP disclosed
WO-2008110242-A1 CROSS-LINKABLE POLYMER DISPERSIONS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF CELANESE EMULSIONS GMBH (DE) 2008-09-18 WO disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 TRPV1 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.